Literature DB >> 3770069

Pharmacokinetics of cimetidine after subchronic administration.

T W Chin, M Spino, S M MacLeod, W A Mahon, S J Soldin.   

Abstract

The influence of cimetidine on its own pharmacokinetics after subchronic administration was assessed in 8 healthy volunteers, aged 26-29 years. On control Day 1, each subject received cimetidine 300 mg i.v., and serum and urine samples were obtained. Each subject was initiated on cimetidine 600 mg b.i.d. orally for 2 weeks. There were 3 further study days repeated after 1 and 2 weeks of cimetidine dosing and 1 week after stopping cimetidine. There was no significant difference in the mean total body clearance of cimetidine among the 4 study days. Mean elimination t1/2 beta and V beta were similarly unchanged. However mean renal clearance (CLR) and fe were significantly increased following 2 weeks of drug dosing (CLR 5.41 ml X min-1 X kg-1; fe 0.61) compared to control (CLR 4.00 ml X min-1 X kg-1; fe 0.48). Although the non renal clearance was reduced from control values of 4.29 to 3.51 ml X min-1 X kg-1 following 2 weeks of dosing the difference was not significant. Dosage adjustment of cimetidine appears unnecessary after short-term dosing in the presence of normal renal function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770069     DOI: 10.1007/bf00608228

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.

Authors:  W L Burland; W A Duncan; T Hesselbo; J G Mills; P C Sharpe; S J Haggie; J H Wyllie
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

2.  Bioavailability and pharmacokinetics of cimetidine.

Authors:  A Grahnén; C von Bahr; B Lindström; A Rosén
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

3.  High performance liquid chromatographic analysis of cimetidine in serum.

Authors:  S J Soldin; D R Fingold; P C Fenje; W A Mahon
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

4.  Pharmacokinetic studies of cimetidine and ranitidine before and after treatment in peptic ulcer patients.

Authors:  G W Mihaly; D B Jones; J A Anderson; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

5.  Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.

Authors:  D R Guay; G R Matzke; H N Bockbrader; J Dancik
Journal:  Clin Pharm       Date:  1983 Mar-Apr

Review 6.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients.

Authors:  A Somogyi; H G Rohner; R Gugler
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

8.  Cimetidine-a clinical and pharmacokinetic study.

Authors:  J Webster; H E Barber; G M Hawksworth; T A Jeffers; J Petersen; J C Petrie; P W Brunt; N A Mowat; R Griffiths
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

9.  Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents.

Authors:  K V Speeg; R V Patwardhan; G R Avant; M C Mitchell; S Schenker
Journal:  Gastroenterology       Date:  1982-01       Impact factor: 22.682

10.  Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration.

Authors:  R E Vestal; K E Thummel; B Musser; G D Mercer
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.